FDA Approves New Drug For Early Treatment Of Alzheimer’s

WHITE OAK, MD - JULY 20: A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland. (Photo by Sarah Silbiger/Getty Images)

At a glance

  • The U.S. Food and Drug Administration on Friday approved a new drug to treat Alzheimer’s disease.
  • Testing reportedly showed considerable success in helping patients with the debilitating condition.
  • The FDA said in a press release that it had approved the drug Leqembi for Alzheimer’s patients. The drug is “the second of a new category of medications approved for Alzheimer’s disease that target the fundamental pathophysiology of the disease,” the agency said.
  • Testing of the drug reportedly showed it having “a statistically significant reduction in brain amyloid plaque,” one of the chief signs of Alzheimer’s progression.

Top News Stories

You May Like: